RedHill Biopharma expands at-the-market offering capacity by $2.128 million

RedHill Biopharma Ltd. filed a prospectus supplement dated June 29, 2026, supplementing a prospectus originally dated August 19, 2024 under registration statement Form F-3, which had already been supplemented on February 3, 2025, November 26, 2025, and May 7, 2026.¹

The supplement covers the sale of American Depositary Shares, each representing ten thousand ordinary shares, under an At The Market Offering Agreement RedHill entered into with H.C. Wainwright & Co., LLC on February 3, 2025.¹

RedHill filed the supplement to increase the maximum aggregate offering amount of ADSs that may be sold under the sales agreement going forward.¹ After accounting for the $2,178,154 offering limit under General Instruction I.B.5 of Form F-3, and subtracting amounts already sold under that instruction over the prior 12 months, RedHill may now offer and sell up to $2,128,000 in additional ADSs, on top of $49,690 in ADSs already sold under the prospectus and sales agreement.¹

As of the filing date, the aggregate market value of RedHill's outstanding ordinary shares held by non-affiliates was $6,534,464, based on 59,949,221,000 shares outstanding held by non-affiliates, equivalent to 5,994,922 ADSs, using an ADS price of $1.09 as of the Nasdaq closing price on April 30, 2026.¹ The company said it had sold 54,954 ADSs under the sales agreement for gross proceeds of about $49,690 during the 12 months preceding the filing.¹

Under Form F-3's General Instruction I.B.5, RedHill cannot sell registered securities in a public primary offering exceeding one-third of its non-affiliate-held public float in any 12-month period while that float remains below $75.0 million.¹

The ADSs trade on Nasdaq under the symbol "RDHL," and closed at $0.8786 per ADS on June 26, 2026.¹ The filing states that investing in the securities involves a high degree of risk.¹